Skip to main content
. 2020 Nov 26;4(Suppl 1):28–49. doi: 10.1159/000512500

Table 2.

Examples of representative collaborations and their role in addressing gaps for DHT

Initiative Purpose Scope/platform Gap addressed Reference
Digital Medicine Society Digital medicine applications for public health through interdisciplinary collaboration, research, and teaching Disease and platform agnostic Consensus 22

Personalized Parkinson's Project Deep and frequent phenotyping of people with PD to understand interindividual variability in disease progression Single site in The Netherlands/Verily Compliance, standard operating procedures, patient focused, open science, advancement of interchangability across studies 31

The Parkinson's Progression Markers Initiative Identification and validation of novel biomarkers in PD Global multisite/ Roche and Verily Standards, open science, alignment with PD trials 28

Oxford Parkinson's Discovery Cohort Translational research and unravel heterogeneity of PD throughout all stages of the PD continuum UK multi-site/android app Identification of at-risk individuals 32

Michael J. Fox Foundation Digital Health Consortium Improve the development of therapeutics for PD through the use of digital endpoints Multiple platforms Metadata standards, open science, facilitate interchangability across studies 35

Movement Disorder Society Task Force on Technology Diagnostic and therapeutic potential of technology for movement disorders N/A Effective use of DHT in clinical care of movement disorders 14, 21

Innovative Medicines Initiative Mobilise-D Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement − chronic obstructive pulmonary disease, PD, multiple sclerosis, hip fracture recovery, and congestive heart failure Single platform to be defined Improve the accurate assessment of mobility in clinical trials 38